1
|
Wefel JS, Zhou R, Sulman EP, Boehling NS, Armstrong GN, Tsavachidis S, Liang FW, Etzel CJ, Kahalley LS, Small BJ, Scheurer ME, Bondy ML, Liu Y. Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients. J Neurooncol 2021; 156:185-193. [PMID: 34817796 DOI: 10.1007/s11060-021-03905-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Accepted: 11/17/2021] [Indexed: 11/24/2022]
Abstract
PURPOSE Impaired neurocognitive function (NCF) is extremely common in patients with higher grade primary brain tumor. We previously reported evidence of genetic variants associated with NCF in glioma patients prior to treatment. However, little is known about the effect of genetic variants on NCF decline after adjuvant therapy. METHODS Patients (N = 102) completed longitudinal NCF assessments that included measures of verbal memory, processing speed, and executive function. Testing was conducted in the postoperative period with an average follow up interval of 1.3 years. We examined polymorphisms in 580 genes related to five pathways (inflammation, DNA repair, metabolism, cognitive, and telomerase). RESULTS Five polymorphisms were associated with longitudinal changes in processing speed and 14 polymorphisms with executive function. Change in processing speed was strongly associated with MCPH1 rs17631450 (P = 2.2 × 10-7) and CCDC26 rs7005206 (P = 9.3 × 10-7) in the telomerase pathway; while change in executive function was more strongly associated with FANCF rs1514084 (P = 2.9 × 10-6) in the DNA repair pathway and DAOA rs12428572 (P = 2.4 × 10-5) in the cognitive pathway. Joint effect analysis found significant genetic-dosage effects for longitudinal changes in processing speed (Ptrend = 1.5 × 10-10) and executive function (Ptrend = 2.1 × 10-11). In multivariable analyses, predictors of NCF decline included progressive disease, lower baseline NCF performance, and more at-risk genetic variants, after adjusting for age, sex, education, tumor location, histology, and disease progression. CONCLUSION Our longitudinal analyses revealed that polymorphisms in telomerase, DNA repair, and cognitive pathways are independent predictors of decline in NCF in glioma patients.
Collapse
Affiliation(s)
- Jeffrey S Wefel
- Section of Neuropsychology, Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 431, Houston, TX, 77030, USA.
| | - Renke Zhou
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA
| | - Erik P Sulman
- Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA
| | - Nicholas S Boehling
- Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA
| | - Georgina N Armstrong
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA
| | - Spiridon Tsavachidis
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA
| | - Fu-Wen Liang
- Institute of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Carol J Etzel
- Biostatistics, Corrona, LLC, Southborough, MA, 01772, USA
| | - Lisa S Kahalley
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, 77030, USA
| | - Brent J Small
- School of Aging Studies, University of South Florida, 4202 E Fowler Avenue, Tampa, FL, 33620, USA
| | - Michael E Scheurer
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA
| | - Melissa L Bondy
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA.
| | - Yanhong Liu
- Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, One Baylor Plaza, Mailstop BCM305, Houston, TX, 77030, USA.
| |
Collapse
|
2
|
Ni P, Liu M, Wang D, Tian Y, Zhao L, Wei J, Yu X, Qi X, Li X, Yu H, Ni R, Ma X, Deng W, Guo W, Wang Q, Li T. Association Analysis Between Catechol-O-Methyltransferase Expression and Cognitive Function in Patients with Schizophrenia, Bipolar Disorder, or Major Depression. Neuropsychiatr Dis Treat 2021; 17:567-574. [PMID: 33654399 PMCID: PMC7910219 DOI: 10.2147/ndt.s286102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2020] [Accepted: 01/22/2021] [Indexed: 02/05/2023] Open
Abstract
INTRODUCTION Schizophrenia, bipolar disorder (BD), and major depressive disorder are three common mental disorders. Although their diagnosis and treatment differ, they partially overlap. METHODS To explore the similarities and characteristics of these three psychiatric diseases, an intelligence quotient (IQ) assessment was performed to evaluate cognitive deficits. Relative catechol-O-methyltransferase (COMT) expression in peripheral blood mononuclear cells was examined in all three groups compared with healthy controls (HCs). RESULTS The results indicated that patients with any of the three psychiatric diseases presented IQ deficits, and that the first-episode schizophrenia (FES) group had even lower cognitive function than the other two groups. The relative COMT expression decreased in the FES group and increased in the BD group compared with the HC group. The correlation analysis of COMT expression level and IQ scores showed a positive correlation between relative COMT expression and full-scale IQ in the HC group. However, this correlation disappeared in all three psychiatric diseases studied. CONCLUSION In conclusion, this cross-disease strategy provided important clues to explain lower IQ scores and dysregulated COMT expression among three common mental illnesses.
Collapse
Affiliation(s)
- Peiyan Ni
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Manli Liu
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Dequan Wang
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Yang Tian
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Liansheng Zhao
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Jinxue Wei
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Xueli Yu
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Xueyu Qi
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Xiaojing Li
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Hua Yu
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Rongjun Ni
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Xiaohong Ma
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Wei Deng
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Wanjun Guo
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Qiang Wang
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China
| | - Tao Li
- The Psychiatric Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Mental Health Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Huaxi Brain Research Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.,Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangzhou, People's Republic of China
| |
Collapse
|
3
|
The impact of COMT polymorphisms on cognition in Bipolar Disorder: A review: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J Affect Disord 2019; 243:545-551. [PMID: 30146088 DOI: 10.1016/j.jad.2018.08.009] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 07/24/2018] [Accepted: 08/06/2018] [Indexed: 11/22/2022]
Abstract
BACKGROUND Cognitive deficits represent a core feature of Bipolar Disorder. The dopamine system is considered fundamental for cognitive functions relying on prefrontal cortex, such as attention and executive functions. A genetic regulation of prefrontal dopamine has been described and the catechol-O-methyltransferase (COMT) has been extensively studied in relation to numerous psychiatric phenotypes, especially because of the involvement of its polymorphisms in the regulation of cognitive functions. Specifically, the Val158Met polymorphism greatly alters COMT function and cognitive performance in both psychiatric disorders and healthy controls. However, only few studies assessed the association between COMT polymorphisms and cognitive functions in bipolar disorder (BD) subjects and this association might help in the comprehension of cognitive alterations in BD. METHODS In this context, the present review summarizes results from genetic studies that investigated COMT genetic modulation on cognitive performance in patients affected by BD. RESULTS Overall the results confirmed that (a) COMT Val158Met polymorphism is associated with altered cognitive functions in BD patients, especially in the domains of memory, executive functions and emotion detection; and (b) COMT genotype may interact with both mood episodes and pharmacologic treatments in determining the cognitive profile of these subjects. LIMITATIONS Few genetic studies exploring COMT genetic effect on cognition in BD. CONCLUSIONS These findings seem to indicate a role of COMT polymorphisms in regulating cognitive functioning in patients with BD. The genetically determined dopaminergic tone may be further affected by mood episodes and pharmacological treatments.
Collapse
|
4
|
Howard DM, Adams MJ, Clarke TK, Wigmore EM, Zeng Y, Hagenaars SP, Lyall DM, Thomson PA, Evans KL, Porteous DJ, Nagy R, Hayward C, Haley CS, Smith BH, Murray AD, Batty GD, Deary IJ, McIntosh AM. Haplotype-based association analysis of general cognitive ability in Generation Scotland, the English Longitudinal Study of Ageing, and UK Biobank. Wellcome Open Res 2017; 2:61. [PMID: 28989979 PMCID: PMC5605947 DOI: 10.12688/wellcomeopenres.12171.1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/07/2017] [Indexed: 01/07/2023] Open
Abstract
Background: Cognitive ability is a heritable trait with a polygenic architecture, for which several associated variants have been identified using genotype-based and candidate gene approaches. Haplotype-based analyses are a complementary technique that take phased genotype data into account, and potentially provide greater statistical power to detect lower frequency variants. Methods: In the present analysis, three cohort studies (n
total = 48,002) were utilised: Generation Scotland: Scottish Family Health Study (GS:SFHS), the English Longitudinal Study of Ageing (ELSA), and the UK Biobank. A genome-wide haplotype-based meta-analysis of cognitive ability was performed, as well as a targeted meta-analysis of several gene coding regions. Results: None of the assessed haplotypes provided evidence of a statistically significant association with cognitive ability in either the individual cohorts or the meta-analysis. Within the meta-analysis, the haplotype with the lowest observed
P-value overlapped with the D-amino acid oxidase activator (
DAOA) gene coding region. This coding region has previously been associated with bipolar disorder, schizophrenia and Alzheimer’s disease, which have all been shown to impact upon cognitive ability. Another potentially interesting region highlighted within the current genome-wide association analysis (GS:SFHS:
P = 4.09 x 10
-7), was the butyrylcholinesterase (
BCHE) gene coding region. The protein encoded by
BCHE has been shown to influence the progression of Alzheimer’s disease and its role in cognitive ability merits further investigation. Conclusions: Although no evidence was found for any haplotypes with a statistically significant association with cognitive ability, our results did provide further evidence that the genetic variants contributing to the variance of cognitive ability are likely to be of small effect.
Collapse
Affiliation(s)
- David M Howard
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
| | - Mark J Adams
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
| | - Toni-Kim Clarke
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
| | - Eleanor M Wigmore
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK
| | - Yanni Zeng
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.,Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Saskia P Hagenaars
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.,Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.,Department of Psychology, University of Edinburgh, Edinburgh, UK
| | - Donald M Lyall
- Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Pippa A Thomson
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.,Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Kathryn L Evans
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.,Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - David J Porteous
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Reka Nagy
- Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Caroline Hayward
- Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.,Generation Scotland, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Chris S Haley
- Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Blair H Smith
- Generation Scotland, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.,Division of Population Health Sciences, University of Dundee, Dundee, UK
| | - Alison D Murray
- Generation Scotland, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.,Aberdeen Biomedical Imaging Centre, University of Aberdeen, Aberdeen, UK
| | - G David Batty
- Department of Epidemiology and Public Health, University College London, London, UK
| | - Ian J Deary
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.,Department of Psychology, University of Edinburgh, Edinburgh, UK.,Generation Scotland, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Andrew M McIntosh
- Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.,Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK.,Generation Scotland, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
5
|
Flowers SA, Ryan KA, Lai Z, McInnis MG, Ellingrod VL. Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. BMC Psychol 2016; 4:14. [PMID: 27039372 PMCID: PMC4818866 DOI: 10.1186/s40359-016-0118-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 03/24/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Second generation antipsychotics (SGAs) are increasingly utilized in Bipolar Disorder (BD) but are potentially associated with cognitive side effects. Also linked to cognitive deficits associated with SGA-treatment are catechol-O-methyltransferase (COMT) gene variants. In this study, we examine the relationship between cognition in SGA use and COMT rs5993883 in cohort sample of subjects with BD. METHODS Interactions between SGA-treatment and COMT rs5993883 genotype on cognition was tested using a battery of neuropsychological tests performed in cross-sectional study of 246 bipolar subjects. RESULTS The mean age of our sample was 40.15 years and was comprised of 70 % female subjects. Significant demographic differences included gender, hospitalizations, benzodiazepine/antidepressant use and BD-type diagnosis. Linear regressions showed that the COMT rs5993883 GG genotype predicted lower verbal learning (p = 0.0006) and memory (p = 0.0026) scores, and lower scores on a cognitive control task (p = 0.004) in SGA-treated subjects. Interestingly, COMT GT- or TT-variants showed no intergroup cognitive differences. Further analysis revealed an interaction between SGA-COMT GG-genotype for verbal learning (p = 0.028), verbal memory (p = 0.026) and cognitive control (p = 0.0005). CONCLUSIONS This investigation contributes to previous work demonstrating links between cognition, SGA-treatment and COMT rs5993883 in BD subjects. Our analysis shows significant associations between cognitive domains such as verbal-cognition and cognitive control in SGA-treated subjects carrying the COMT rs5993883 GG-genotype. Prospective studies are needed to evaluate the clinical significance of these findings.
Collapse
Affiliation(s)
- Stephanie A Flowers
- Clinical Pharmacy Department, College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, MI, 48109-106, USA
| | - Kelly A Ryan
- Department of Psychiatry, School of Medicine, University of Michigan, 4250 Plymouth Rd, Ann Arbor, MI, 48109, USA
| | - Zongshan Lai
- Department of Psychiatry, School of Medicine, University of Michigan, 4250 Plymouth Rd, Ann Arbor, MI, 48109, USA.,Center for Clinical Management Research (CCMR) Veterans Affairs, Ann Arbor, USA
| | - Melvin G McInnis
- Department of Psychiatry, School of Medicine, University of Michigan, 4250 Plymouth Rd, Ann Arbor, MI, 48109, USA
| | - Vicki L Ellingrod
- Clinical Pharmacy Department, College of Pharmacy, University of Michigan, 428 Church St, Ann Arbor, MI, 48109-106, USA. .,Department of Psychiatry, School of Medicine, University of Michigan, 4250 Plymouth Rd, Ann Arbor, MI, 48109, USA.
| |
Collapse
|
6
|
Tan J, Lin Y, Su L, Yan Y, Chen Q, Jiang H, Wei Q, Gu L. Association between DAOA gene polymorphisms and the risk of schizophrenia, bipolar disorder and depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2014; 51:89-98. [PMID: 24447945 DOI: 10.1016/j.pnpbp.2014.01.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/21/2013] [Revised: 01/09/2014] [Accepted: 01/10/2014] [Indexed: 01/09/2023]
Abstract
OBJECTIVE Schizophrenia (SCZ), bipolar disorder (BD) and depressive disorder (DD) are common psychiatric disorders, which show common genetic vulnerability. Previous gene-disease association studies have reported correlations between d-amino acid oxidase activator (DAOA) gene polymorphisms and the three psychiatric disorders. However, the findings were contradictory. A meta-analysis was therefore conducted to provide more robust investigations into DAOA polymorphisms and the risk of SCZ, BD and DD. METHODS This meta-analysis recruited 46 published studies up to July 2013, including 17,515 cases and 25,189 controls. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the association between three specific DAOA SNPs and SCZ, BD and DD. Publication bias was tested by Begg's test and funnel plot, and heterogeneity was assessed by the Cochran's chi-square-based Q statistic and the inconsistency index (I(2)). Moreover, the robustness of the findings was estimated by cumulative meta-analysis. RESULTS DAOA genetic polymorphisms (M15, M18 and M23) were not found to confer a statistically significant increased risk of SCZ, BD or DD in the overall sample, or in Caucasians and Asians following subgroup analysis. CONCLUSION The current study indicated that M15, M18 and M23 might not be the risk factor for SCZ, BD or DD. However, further studies are required to provide robust evidence to estimate the association between DAOA polymorphisms and psychiatric disorders.
Collapse
Affiliation(s)
- Jinjing Tan
- Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, Guangxi, China
| | - Yu Lin
- School of Preclinical Medicine of Guangxi Medical University, Nanning, Guangxi, China
| | - Li Su
- School of Public Health of Guangxi Medical University, Nanning, Guangxi, China
| | - Yan Yan
- Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, Guangxi, China
| | - Qing Chen
- Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, Guangxi, China
| | - Haiyun Jiang
- Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, Guangxi, China
| | - Qiugui Wei
- Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, Guangxi, China
| | - Lian Gu
- Department of Internal Neurology, First Affiliated Hospital, Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, Guangxi, China.
| |
Collapse
|